| Autor: |
Markowitsch SD; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Pham T; Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany., Rutz J; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Chun FK; Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany., Haferkamp A; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Tsaur I; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Juengel E; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Ries N; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Thomas A; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany., Blaheta RA; Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany. |
| Abstrakt: |
Background : Plant derived isolated compounds or extracts enjoy great popularity among cancer patients, although knowledge about their mode of action is unclear. The present study investigated whether the combination of two herbal drugs, the cyanogenic diglucoside amygdalin and the isothiocyanate sulforaphane (SFN), influences growth and proliferation of renal cell carcinoma (RCC) cell lines. Methods : A498, Caki-1, and KTCTL-26 cells were exposed to low-dosed amygdalin (1 or 5 mg/mL), or SFN (5 µM) or to combined SFN-amygdalin. Tumor growth and proliferation were analyzed by MTT, BrdU incorporation, and clone formation assays. Cell cycle phases and cell cycle-regulating proteins were analyzed by flow cytometry and Western blotting, respectively. The effectiveness of the amygdalin-SFN combination was determined using the Bliss independence model. Results : 1 mg/mL amygdalin or 5 µM SFN, given separately, did not suppress RCC cell growth, and 5 mg/mL amygdalin only slightly diminished A498 (but not Caki-1 and KTCTL-26) cell growth. However, already 1 mg/mL amygdalin potently inhibited growth of all tumor cell lines when combined with SFN. Accordingly, 1 mg/mL amygdalin suppressed BrdU incorporation only when given together with SFN. Clonogenic growth was also drastically reduced by the drug combination, whereas only minor effects were seen under single drug treatment. Superior efficacy of co-treatment, compared to monodrug exposure, was also seen for cell cycling, with an enhanced G0/G1 and diminished G2/M phase in A498 cells. Cell cycle regulating proteins were altered differently, depending on the applied drug schedule (single versus dual application) and the RCC cell line, excepting phosphorylated Akt which was considerably diminished in all three cell lines with maximum effects induced by the drug combination. The Bliss independence analysis verified synergistic interactions between amygdalin and SFN. Conclusions : These results point to synergistic effects of amygdalin and SFN on RCC cell growth and clone formation and Akt might be a relevant target protein. The combined use of low-dosed amygdalin and SFN could, therefore, be beneficial as a complementary option to treat RCC. To evaluate clinical feasibility, the in vitro protocol must be applied to an in vivo model. |
